Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Core One Labs Inc. (C:COOL)

Business Focus: Alternative Medicine

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for COOL within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 18, 2022 19:55 ET
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
VANCOUVER, BC / ACCESSWIRE / November 18, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce the initial production run of its psilocybin active pharmaceutical ingredient (API) product at a good manufacturing practices (GMP) facility is projected for January 2023, to test the Company's commercial production capabilities.
Read full article
Oct 21, 2022 19:55 ET
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
VANCOUVER, BC / ACCESSWIRE / October 21, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") is pleased to announce, as a follow up to the Company's press release dated March 20, 2022, wherein the Company announced that it was actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies, that the Company's Board of Directors is now taking all n
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.32
--
--
Price to Sales - TTM
45.61
4.14
4.47
Price to Book - most recent quarter
6.32
1.10
1.67
Price to Cash Flow per share - TTM
--
7.75
9.11
Price to Free Cash Flow per share - TTM
--
9.11
12.54
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 30, 2022171,023-72,740
Nov 15, 2022243,763-183,156
Oct 31, 2022426,91948,380
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Core One Labs Inc. is a Canada-based life sciences and biotechnology company. The Company is focused on research, development, and production of biologically synthesized (biosynthesized) current Good Manufacturing Practice (cGMP) API grade psychedelic compounds, as well as the advancement of psychedelic assisted modalities for the treatment of various mental health and neurological disorders. It has developed a thin film oral strip (the technology), which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining bioavailability. It focuses on further developing and applying the technology to psychedelic compounds, such as psilocybin. The Company is developing a pipeline of cGMP psychedelic compounds for the furtherance of mental health and neurological disorders research. The Company also holds an interest in medical clinics, which maintain a combined database of over 275,000 patients.

See business summary

 

Twitter

Search (past week) for $COOL.CA

  • No tweets found